Guangzhou Baiyunshan Pharmaceutical Holdings (874.HK) - Conservative About the Outlook
This insight analyzed Baiyunshan’s 2021Q3 performance, the core business segments, the comparison with peers, the concerns on business transition,...
624 Views
Pre-IPO HTDK Medical Holdings - Policy Risk Is the Biggest Uncertainty
The article mainly analyzed HTDK Medical Holdings in terms of the industry characteristics, the potential policy risk, the business, the financial...
430 Views
Pre-IPO Guangzhou Pharmaceuticals - The Risk Points Gradually Emerged
As Guangzhou Pharmaceuticals submitted the IPO application, the risk points emerged considering the competition pattern, new policies and business...
432 Views
Screening the Silk Road: Q1 2021 All Cap Screening - Free Cashflow (FCF)
With the value/growth investment style ratio at 20-year lows, we present 27 names which hold characteristics worthy of further review.
348 Views
Initiating Coverage of CR Pharma With Narrow Moat Rating and HKD 13.20 FVE
We initiate coverage on China Resources Pharmaceutical (3320 HK) with a narrow moat rating and a fair value estimate of HKD 13.20 per share. This...
502 Views